givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acute Intermittent Porphyria

Conditions

Acute Intermittent Porphyria

Trial Timeline

May 6, 2015 → Sep 6, 2017

NCT ID

NCT02452372

About givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)

givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Acute Intermittent Porphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT02452372. Target conditions include Acute Intermittent Porphyria.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02452372	Phase 1	Completed	May 6, 2015	Sep 6, 2017	Acute Intermittent Porphyria

Competing Products

20 competing products in Acute Intermittent Porphyria

See all competitors

Product	Company	Stage	Hype Score
AFM28	Affimed	Phase 1	25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + Placebo	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
TRV130	Trevena	Phase 3	69
TRV130 + Morphine + Placebo	Trevena	Phase 2	44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen	CSPC Pharmaceutical Group Limited	Phase 2	51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells	CSPC Pharmaceutical Group Limited	Phase 2	51
SPT-07A injection	Sinopharm	Phase 3	76
PRGN-3006 T Cells	Precigen	Phase 1	28
Bisantrene	Race Oncology	Phase 2	44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine	Race Oncology	Phase 1	25
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	44
ZN-d5 ZN-c3 + ZN-c3	Zentalis Pharmaceuticals	Phase 1/2	33
ZN-d5	Zentalis Pharmaceuticals	Phase 1	25
VIP943 (QW) + VIP943 (BIW)	Vincerx Pharma	Phase 1	25
LY2523355	Eli Lilly	Phase 1	33
Tomivosertib	eFFECTOR Therapeutics	Phase 1	25
gemtuzumab ozogamycin	Chugai Pharmaceutical	Phase 3	77

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3

Givosiran + PlaceboPhase 3

Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3

LumasiranPhase 3